Solexa (www.solexa.com) claims that its new technology will transform sequencing by reducing cost and increasing throughput. “Our technology will offer a hundred-fold improvement in productivity and a ...

Illumina (NASDAQ:ILMN) on Monday lowered its adjusted profit outlook and cut spending costs for 2025 as the company grapples with a Chinese ban on its gene sequencers. Illumina now expects fiscal 2025 ...

Bangalore (Reuters) - Companies that make the gene-sequencing devices used in scientific research face a tough few years as potential cuts to the U.S. federal budget squeeze funding to its main ...

At a tenth of the price, and many times faster than conventional methods, a new gene sequencer looks set to revolutionize the life sciences. Share on Facebook (opens in a new window) Share on X (opens ...

When it comes to DNA, France has always been behind the times. Never mind the hefty fines and prison sentence a man apparently can get for trying to order a paternity test, it seems that just knowing ...

llumina on Thursday forecast core business revenue to be nearly flat in the coming year compared to 2023 amid subdued demand for its genetic testing tools and diagnostics products. The San Diego-based ...

Elucidating the relationship between the sequences of non-coding regulatory elements and their target genes is key to understanding gene regulation and its variation between plant species and ecotypes ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

SANTA CLARA, CA--(Marketwire - Oct 31, 2012) - NVIDIA® Tesla® GPU accelerators are enabling Life Technologies Corporation's new Ion Proton™ System to accelerate primary genome-sequence analysis-- the ...

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader. Bionano Genomics is unproven but expanding quickly. So ...

With shares of the gene sequencing giant Illumina (NASDAQ: ILMN) collapsing by 53% over the last three years due to a combination of a botched acquisition attempt and weakness in its core business, ...

On June 11, the gene sequencing giant Illumina (NASDAQ: ILMN) announced that its CEO, Francis deSouza, resigned after a tenure of roughly 10 years and that the company would start looking for a ...